Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 196.16 thousand shares for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2022-08-15
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-06-30 was 95.26K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-03-31 was 100.91K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2021-12-31 was -26.89K shares.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 307.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2022-06-30 | 95.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 196.16K shares 10-Q · filed 2022-08-15 | 169.27K shares derived: sum of 3 quarters · filed 2022-08-15 | |
| 2022-03-31 | 100.91K shares 10-Q · filed 2022-05-13 | 74.02K shares derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | -26.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 307.00K shares 10-K · filed 2022-03-29 | ||
| 2021-09-30 | 333.89K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |